General Director of Biogen Idec faces many difficult decisions about long-term drug for multiple sclerosis, which is headed by an early approval FDA. The first in a series devoted to the operational decisions due to drive early adoption. Sparks leaders to discuss the economic, legal and ethical responsibilities in several constituencies, and as a leader can lead the company to fulfill these responsibilities effectively, in a difficult situation. The decisions facing the company include how to maintain robust research on the effectiveness and safety of the drug, how to increase manufacturing capacity to meet anticipated demand, and how to protect the insurer reimbursement. All these problems occur on the background of accelerating the approval process, the uncertainty that the FDA will ultimately decide, and whether the company really needs to hold an early statement. "Hide
by Joshua D. Margolis, Thomas J. DeLong Source: Harvard Business School 17 pages. Publication Date: November 14, 2007. Prod. #: 408025-PDF-ENG
Related Case Solutions & Analyses:
Jabwood International: The Risky Business of Expanding East
Corporate governance reforms and our regulatory future
ChemChina
Hungary: Economic Crisis and a Shift to the Right
Using Decision Errors to Help People Help Themselves
From Patrimonio Hoy to Arte en Concreto: Tailoring a Social Responsibility Program at CEMEX Puerto Rico
As Green As It Gets
Greenspans Conundrum
Revising Electricity Tariffs in Brazil
Illustrating the Financial Benefits of Green Chemistry
